JPRN-UMIN000047301招募中未知
avalglucosidase alfa Special Drug Use Investigation for patients with pompe disease - avalglucosidase alfa Special Drug Use Investigation for patients with pompe disease
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- Sanofi K.K.
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •-Individuals participating in or enrolling in other clinical trials involving therapeutic interventions of Nexviazyme -Those with off-label use of Nexviazyme
研究者
相似试验
已完成
不适用
A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care SettingMucopolysaccharidosis Type I (MPS I)Pompe DiseaseNCT05073783Sanofi57
已完成
2 期
Avalglucosidase Alfa Extension StudyGlycogen Storage Disease Type II Pompe DiseaseNCT02032524Genzyme, a Sanofi Company19
终止
4 期
A Noninferiority Study of Alglucosidase Alfa Manufactured at the 160 L and 4000 L Scales in Treatment Naïve Patients With Infantile-Onset Pompe DiseasePompe Disease (Infantile-Onset)Glycogen Storage Disease Type II (GSD II)Glycogenosis 2Acid Maltase DeficiencyNCT01597596Genzyme, a Sanofi Company4
招募中
不适用
Effects of alfa glucosidase inhibitors (miglitol, voglibose) on efficacy and safety in type 2 diabetic patients with coronary artery disease.type 2 diabetes patients with coronary artery diseaseJPRN-UMIN000005777niversity of Fukui Faculty of Medical Sciences40
终止
不适用
Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGTImpaired Glucose ToleranceMyocardial InfarctionNCT00212017National Cerebral and Cardiovascular Center, Japan3,000